PMID- 16911776
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20070724
LR  - 20220318
IS  - 1746-1596 (Electronic)
IS  - 1746-1596 (Linking)
VI  - 1
DP  - 2006 Aug 15
TI  - Stratification of non-small cell lung cancer patients for therapy with epidermal 
      growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization 
      assay.
PG  - 19
AB  - DNA fluorescence in situ hybridization (FISH) technology is used to study 
      chromosomal and genomic changes in fixed cell suspensions and tissue block 
      preparations. The technique is based on specific hybridization of small labeled 
      DNA fragments, the probes, to complementary sequences in a target DNA molecule. 
      Demand for FISH assays in formalin-fixed, paraffin-embedded tissues has been 
      increasing, mainly in conditions in which diagnosis is not achieved in cell 
      smears or tissue imprints, such as solid tumors. Moreover, the development of 
      molecular targeted therapies in oncology has expanded the applicability of tests 
      to predict sensitivity or resistance to these agents. The efficient use of 
      tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) 
      as therapeutical agents in advanced non-small cell lung cancer (NSCLC) depends on 
      identification of patients likely to show clinical benefit from these specific 
      treatments. The EGFR gene copy number determined by FISH has been demonstrated as 
      an effective predictor of outcome from NSCLC patients to EGFR TKIs; however there 
      are pending challenges for standardization of laboratory procedures and 
      definition of the scoring system. This methodology article focuses on the EGFR 
      FISH assay. It details the scoring system used in the studies conducted at the 
      University of Colorado Cancer Center in which a significant association was found 
      between increased EGFR copy numbers and clinical outcome to TKIs, and proposes 
      interpretative guidelines for molecular stratification of NSCLC patients for TKI 
      therapy.
FAU - Varella-Garcia, Marileila
AU  - Varella-Garcia M
AD  - University of Colorado Health Sciences Center, Cancer Center, Aurora, CO, USA. 
      marileila.garcia@uchsc.edu
LA  - eng
GR  - P30 CA046934/CA/NCI NIH HHS/United States
GR  - P50 CA058187/CA/NCI NIH HHS/United States
GR  - U01 CA085070/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20060815
PL  - England
TA  - Diagn Pathol
JT  - Diagnostic pathology
JID - 101251558
PMC - PMC1560164
EDAT- 2006/08/17 09:00
MHDA- 2006/08/17 09:01
PMCR- 2006/08/15
CRDT- 2006/08/17 09:00
PHST- 2006/07/04 00:00 [received]
PHST- 2006/08/15 00:00 [accepted]
PHST- 2006/08/17 09:00 [pubmed]
PHST- 2006/08/17 09:01 [medline]
PHST- 2006/08/17 09:00 [entrez]
PHST- 2006/08/15 00:00 [pmc-release]
AID - 1746-1596-1-19 [pii]
AID - 10.1186/1746-1596-1-19 [doi]
PST - epublish
SO  - Diagn Pathol. 2006 Aug 15;1:19. doi: 10.1186/1746-1596-1-19.